Loading…
Loading…
AVCTF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AVCTF and 80,000+ other tickers.
See exactly how AVCTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AVCTF and 80,000+ other tickers.
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own…
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair.
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON and PHILADELPHIA, June 01, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today released updated Phase 1a/1b and pharmacokinetics (PK), safety, toxicity and preliminary efficacy data with faridoxorubicin (AVA6000, pre|CISION®-enabled doxorubicin) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Christina Coughlin, CEO of Avacta, commented: "Today's data further underscores our confidence in both our Gen One product faridoxorubicin (AVA6000) and our pre|CISION ® technology to significantly improve treatment options for cancer patients.
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.